CMT Endgame - Ending The Legacy of CMT1A
It’s time to put an end to Charcot-Marie-Tooth disease type 1A
The suffering cannot persist any longer.
We envision the route towards clinical trials, treatments and ultimately, a cure.
Join us as we embark on this journey.
We are on a one-way trip directly to the ENDGAME FOR CMT1A. I, along with other family members, live with CMT and now I see my daughter and niece repeating the cycle. It just has to stop.
The CMT Research Foundation has a strategy called ENDGAME. It is working. We are closer than ever to finding treatments and cures. For the first time in more than 45 years, I am encouraged that the science is at a point where treatments and cures are soon to be a reality.
We can do this together. We WILL cure CMT1A, then use the knowledge and science to cure ALL types of CMT.
Peter deSilva
Board Member & Campaign Chair
Former President – Retail of TD Ameritrade
Fellow, Harvard University Advanced Leadership Initiative
CMT1A: A Debilitating Disease with No Treatments Available, Yet.
3 Reasons Why We’re at a Critical Point:
- Gene therapies are rapidly coming online, and new genomic testing capabilities are available.
- Pharmaceutical companies are now interested and eager to develop treatments for CMT1A.
- Companies new to CMT, in partnership with the CMT Research Foundation, have real power to catalyze and accelerate progress.
Why the CMT Research Foundation: We Make Advances Happen
The CMT Research Foundation’s Scientific Advisory Board identified five key priorities to end CMT. To date, 9 projects have been funded for CMT1A, with 5* of those preparing for clinical trials.
Why We Are Taking This Approach: Two Important Success Stories
Turning $128,000 Into $1 Billion for CMT Drug Development
Novartis acquires DTx Pharma: a company that CMTRF introduced to CMT.
Starting in Academia, Moving to Biotech
Through CMTRF funding, world-renowned CMT scientist and clinician Dr. Kleopas Kleopa built a genetic therapy for CMT1A. It’s now licensed by Armatus Bio.
Contact
For more information, or to schedule a presentation, please contact Susan or Anna.
Susan Ruediger
Co-Founder, Chief Mission Officer 678-595-2817 [email protected]
Anna Combes
VP of Philanthropy
504-669-6984
[email protected]
Address
Suite A209
Atlanta, GA 30319
Phone Number
Media Inquiries
203.521.0352